Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-08-14
2007-08-14
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S318500
Reexamination Certificate
active
10984502
ABSTRACT:
The present invention relates to novel compounds useful in the treatment of androgen receptor associated conditions, such as age-related diseases, pharmaceutical compositions containing at least one of the compounds of the present invention and methods of treating a patient in need of therapy for an androgen receptor associated condition by administering a therapeutically effective amount of at least compound of the present invention.
REFERENCES:
patent: 5556909 (1996-09-01), Desai
patent: 5688808 (1997-11-01), Jones et al.
patent: 5688810 (1997-11-01), Jones et al.
patent: 5693646 (1997-12-01), Jones et al.
patent: 5693647 (1997-12-01), Jones et al.
patent: 5696127 (1997-12-01), Jones et al.
patent: 5696130 (1997-12-01), Jones et al.
patent: 5696133 (1997-12-01), Jones et al.
patent: 2126187 (1971-05-01), None
patent: WO96/19458 (1996-06-01), None
patent: WO97/49709 (1997-12-01), None
Banz, W.J. et al., “Effects of Soy Protein and Soy Phytoestrogens on Symptoms Associated with Cardiovascular Disease in Rats”, Journal of Medicinal Food, vol. 2, Nos. 3-4, pp. 271-273 (1999).
Boeijen, A. et al., “Combinatorial Chemistry of Hydantoins”, Bioorganic & Medicinal Chemistry Letters, vol. 8, pp. 2375-2380 (1998).
Bourguet, W. et al., “Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α”, Nature, vol. 375, pp. 377-382 (1995).
Brzozowski, A.M. et al., “Molecular basis of agonism and antagonism in the oestrogen receptor”, Nature, vol. 389, pp. 753-758 (1997).
Evans, R.M., “The Steroid and Thyroid Hormone Receptor Superfamily”, Science, vol. 240, pp. 889-895 (1988).
Grese, T.A. et al., “Molecular determinants of tissue selectivity in estrogen receptor modulators”, Proc. Natl. Acad. Sci. USA, vol. 94, pp. 14105-14110 (1997).
Hamann, L.G. et al., “Discovery of a Potent, Orally Active, Nonsteroidal Androgen Receptor Agonist: 4-Ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono[5,6-g]-quinoline (LG121071)”, J. Med. Chem., vol. 42, No. 2, pp. 210-212 (1999).
Hamann, L.G. et al., “Synthesis and Biological Activity of a Novel Series of Nonsteroidal, Peripherally Selective Androgen Receptor Antagonists Derived from 1,2-Dihydropyridono[5,6-g]quinolines”, J. Med. Chem., vol. 41, No. 4, pp. 623-639 (1998).
Hempstock, J. et al., “Growth inhibition of prostate cell lines in vitro by phyto-oestrogens”, British Journal of Urology, vol. 82, pp. 560-563 (1998).
Neri, R. et al., “A Biological Profile of a Nonsteroidal Antiandrogen, SCH 13521 (4′-Nitro-3′-Trifluoromethylisobutyranilide)”, Endocrinology, vol. 91, No. 2, pp. 427-437 (1972).
Quella, S.K. et al., “Evaluation of Soy Phytoestrogens for the Treatment of Hot Flashes in Breast Cancer Survivors: A North Central Cancer Treatment Group Trial”, Journal of Clinical Oncology, vol. 18, No. 5, pp. 1068-1074 (2000).
Regal, J.F. et al., “Dietary Phytoestrogens Have Anti-Inflammatory Activity in a Guinea Pig Model of Asthma”, Proc. Soc. Exp. Biol. Med., vol. 223, pp. 372-378 (2000).
Shiau, A.K. et al., “The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen”, Cell, vol. 95, pp. 927-937 (1998).
Smigel, K., “Breast Cancer Prevention Trial Shows Major Benefit, Some Risk”, Journal of the National Cancer Institute, vol. 90, No. 9, pp. 647-648 (1998).
Tanenbaum, D.M. et al., “Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains”, Proc. Natl. Acad. Sci. USA, vol. 95, pp. 5998-6003 (1998).
Vegeto, E. et al., “The Mechanism of RU486 Antagonism Is Dependent on the Conformation of the Carboxy-Terminal Tail of the Human Progesterone Receptor”, Cell, vol. 69, pp. 703-713 (1992).
Bi Yingzhi
Hamann Lawrence G.
Manfredi Mark C.
Simpkins Ligaya M.
Bristol--Myers Squibb Company
Coppins Janet L.
Duncan, Jr. Sammy G.
McKane Joseph K.
Rodney Burton
LandOfFree
Monocyclic N -Aryl hydantoin modulators of androgen... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monocyclic N -Aryl hydantoin modulators of androgen..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monocyclic N -Aryl hydantoin modulators of androgen... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3861301